Tirzepatide (Mounjaro)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tirzepatide (Mounjaro), 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL solution in a single-dose, prefilled pen, or vial for SC use. Indication: For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: As monotherapy when metformin is inappropriate due to contraindication or intolerance In combination with: metformin, or metformin and a sulfonylurea, or metformin and a sodium-glucose cotransporter 2 inhibitor, or basal insulin with or without metformin.